Thyroid microcarcinomas, low-grade prostate cancers, certain neuroendocrine tumors, basal cell carcinomas, and some low-grade lymphomas rank among the slowest growing cancers known to medicine. Some of these tumors take years to double in size, and many never cause symptoms at all during a person’s lifetime. The biology behind this sluggishness varies widely, and in some cases the label “cancer” itself has become controversial because it implies a threat that may never materialize.
How Slow Is Slow?
Oncologists measure tumor growth using a concept called doubling time, which is simply how long it takes a tumor to double in volume. Fast-growing cancers like certain lung or pancreatic cancers can double in weeks. At the other extreme, some slow-growing tumors have doubling times measured in years. In a study of regrowing pituitary adenomas, for instance, tumor doubling times ranged from about 200 days to over 2,500 days, with an average around 930 days, or roughly two and a half years.1PubMed. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas Researchers have found that a marker called Ki-67, which reflects how actively cells are dividing, tracks inversely with doubling time: the lower the Ki-67 index, the slower the growth.2PubMed Central. Relationships between growth rate and Ki-67 and immune indices in ground-glass nodule-featured lung adenocarcinoma
But doubling time alone does not capture everything. A tumor can be biologically dormant for long stretches, then briefly accelerate before stalling again. Others grow so slowly that the person dies of something else before the cancer ever becomes a problem. Understanding the slowest cancers means looking not just at how fast cells divide, but at whether that division ever reaches a pace that matters clinically.
Papillary Thyroid Microcarcinoma
If you had to pick the poster child for indolent cancer, tiny papillary thyroid cancers would be a strong candidate. These are tumors measuring one centimeter or less, and in many cases they barely grow at all. A study tracking patients on active surveillance found that the majority of these tumors were either stable or actually shrank over time: about 57% showed essentially no change, 17% decreased in size, and only 3% grew at what researchers considered a rapid pace.3PubMed. Natural history of papillary thyroid microcarcinoma: Kinetic analyses on tumor volume during active surveillance and before presentation In other words, three quarters of these diagnosed cancers just sat there or got smaller without any treatment.
This does not mean every thyroid microcarcinoma is harmless. Certain features raise concern. One study found that thyroid cancers carrying a BRAF mutation were over four times more likely to fall into the rapid-growth category, and the presence of tiny calcium deposits visible on ultrasound was also linked to faster growth.4PubMed Central. Thyroid BRAF Mutation and Tumor Growth Kinetics during Active Surveillance of Papillary Thyroid Microcarcinoma: A Single-Center Retrospective Study Still, the overall picture for thyroid microcarcinomas is remarkably reassuring. Many clinicians now monitor these tumors with periodic imaging rather than rushing to surgery.
Low-Grade Prostate Cancer
Prostate cancer occupies a unique space in oncology because it is extraordinarily common yet often clinically insignificant. Autopsy studies offer the most striking evidence of this. A systematic review spanning more than 20 countries and six decades found that the prevalence of incidental prostate cancer at autopsy rises steeply with age, reaching an estimated 59% in men over 79.5PubMed Central. Prevalence of incidental prostate cancer: A systematic review of autopsy studies The vast majority of these men never knew they had cancer, and it played no role in their death.
A Japanese autopsy study reinforced this point, finding that latent prostate cancer in men aged 75 to 79 was nearly seven times more common than the rate of clinical diagnosis in that age group.6JAMA Network Open. Trends in the Hidden Burden of Cancer in an Autopsy-Based Study Over 66 Years in Japan For low-grade disease in particular, the tumor can sit in the prostate for decades without spreading, which is why active surveillance has become the recommended management strategy for many men diagnosed with it.
Neuroendocrine Tumors
Neuroendocrine tumors, or NETs, arise from hormone-producing cells scattered throughout the body, most commonly in the gastrointestinal tract and lungs. Well-differentiated NETs tend to be remarkably slow growing, though they can still spread to distant organs like the liver.7PubMed. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors One striking case report described a patient whose liver lesions, visible on imaging, had been present for 11 years before a neuroendocrine tumor was formally diagnosed, highlighting the prolonged and indolent course these cancers can take even when they have already metastasized.8PubMed Central. Slow and Steady: A Slowly Progressing Neuroendocrine Tumor
The challenge with NETs is that “well-differentiated” and “slow” do not always mean “curable.” Some patients live for many years with widespread but indolent disease, managing symptoms like flushing or diarrhea caused by the hormones these tumors secrete. Treatment of advanced NETs remains difficult precisely because their slow growth makes them less responsive to traditional chemotherapy, which works by targeting rapidly dividing cells.
Basal Cell Carcinoma
Basal cell carcinoma is the most commonly diagnosed cancer in many countries, and also one of the least threatening. A systematic review and meta-analysis found that these tumors grow at an average rate of about 0.7 millimeters per month.9PubMed Central. Growth rate of basal cell carcinoma: a meta-analysis and systematic review That works out to less than a centimeter per year. They almost never metastasize, making them dangerous mainly through local tissue destruction if left untreated for years. The typical basal cell carcinoma on someone’s nose or forehead is a slow, locally destructive nuisance rather than a life-threatening disease.
This is not to dismiss basal cell carcinomas entirely. Left alone for a decade or more, they can erode deeply into skin, cartilage, and bone. Certain subtypes are more aggressive than others. But in terms of raw growth speed and systemic danger, they sit near the bottom of the threat scale.
Follicular Lymphoma and Other Indolent Blood Cancers
Among blood cancers, follicular lymphoma is the classic example of an indolent malignancy. It arises from immune cells called B lymphocytes and typically grows so slowly that treating it immediately after diagnosis does not improve survival compared to simply watching and waiting. Studies conducted over 20 years ago established that roughly one in five patients with follicular lymphoma did not need any treatment during the first 10 years after diagnosis.10PubMed Central. Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients? Most clinical guidelines still recommend active surveillance as the default for patients without symptoms.
Chronic lymphocytic leukemia follows a similar pattern for many patients. It can be diagnosed through a routine blood test and may not require treatment for years. But indolent blood cancers carry a risk that solid tumors often do not: transformation into a much more aggressive disease. In chronic lymphocytic leukemia, this is called Richter transformation, and research has shown that the subclones driving this aggressive shift are seeded early in the disease, long before transformation occurs.11PubMed. Early Clones Expand in Richter Transformation of Chronic Lymphocytic Leukemia The possibility of transformation is one reason these patients need ongoing monitoring even when the cancer appears to be doing nothing.
Why Some Cancers Grow So Slowly
The immune system plays a larger role in restraining cancer than most people realize. Decades of research have established that tumors are recognized by the immune system, and their development can be controlled long-term through a process called immunosurveillance.12PubMed Central. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer In many slow-growing cancers, what appears to be inherently sluggish tumor biology is actually a standoff between the cancer and the immune system. This state has been termed cancer-immune equilibrium, a period during which the immune system cannot completely eliminate the cancer but prevents it from progressing or spreading further.13PubMed Central. Cancer-immune equilibrium: questions unanswered
Research into this equilibrium has identified interferon-gamma as a central molecule in maintaining the balance between tumor outgrowth and immune destruction.14PubMed Central. IFNγ is a central node of cancer immune equilibrium This equilibrium phase essentially defines the duration of stable disease. When the balance tips, whether because the immune system weakens or the cancer evolves escape mechanisms, the tumor may begin growing faster. This helps explain why some cancers remain indolent for years or decades and then suddenly become aggressive: the immune truce breaks down.
Beyond immune equilibrium, genuine cellular dormancy is another mechanism. Some cancer cells enter a quiescent state where they simply stop dividing. Researchers have described three models for this: angiogenic dormancy, where the tumor cannot recruit enough blood vessels to grow; immunologic dormancy, the equilibrium state described above; and cellular dormancy, where individual cancer cells become inactive.15PubMed Central. Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis Dormancy is distinct from slow growth. A dormant cancer is not growing slowly; it is not growing at all. But from the patient’s perspective, the practical effect looks the same: the tumor sits quietly, sometimes for years.
The Hidden Cancer Reservoir
One of the most striking findings in modern oncology is that slow-growing cancers are far more common than clinical diagnoses suggest. Autopsy studies consistently reveal cancers that people carried through life without ever knowing. The prostate data is the most dramatic example, but it is not unique. The Japanese autopsy study found that latent thyroid cancer at ages 50 to 54 was present at rates 60 to 95 times higher than the clinical incidence, depending on sex.6JAMA Network Open. Trends in the Hidden Burden of Cancer in an Autopsy-Based Study Over 66 Years in Japan
Breast tissue shows a similar pattern. A systematic review of autopsy studies across ten countries and six decades found that incidental detection of breast cancer in situ and precursor lesions was common in women who were never diagnosed with breast disease during their lives.16PubMed Central. Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta-analysis This large prevalence pool of undetected lesions raises uncomfortable questions about screening. More sensitive tests may detect cancers that would never have caused harm, leading to unnecessary treatment.
The Overdiagnosis Problem
This is where the existence of slow-growing cancers creates a genuine medical dilemma. Screening programs are designed to catch cancer early, when it is most treatable. But if screening uncovers tumors that were never going to cause symptoms or shorten someone’s life, the diagnosis itself becomes the harm. This phenomenon has a name: overdiagnosis. It describes the detection of non-progressive or very slowly progressive lesions that were not destined to cause symptoms or suffering during the person’s remaining lifespan.17PubMed Central. Cancer overdiagnosis: a challenge in the era of screening
Overdiagnosis is not the same as a false positive. A false positive is a test that looks like cancer but turns out not to be. Overdiagnosis is real cancer, confirmed under a microscope, that simply would never have mattered. The distinction is important because overdiagnosed patients receive all the physical and emotional burdens of a cancer diagnosis, including surgery, radiation, or chemotherapy, for a disease that was never going to hurt them. Prostate and thyroid cancers are the two malignancies most frequently cited in overdiagnosis discussions, precisely because they include such large proportions of indolent disease.
Active Surveillance Instead of Immediate Treatment
For many slow-growing cancers, the medical profession has increasingly embraced active surveillance: regular monitoring with imaging and sometimes biopsies, but no treatment unless the cancer shows signs of progressing. This is not the same as ignoring the cancer. It is a structured protocol designed to avoid the side effects of treatment when the cancer poses minimal immediate risk, while still catching the minority of cases that do accelerate.
In early-stage lung cancer, for example, one analysis found that patients managed with active surveillance had a longer median overall survival of about 49 months, compared with roughly 27 months for patients who received no treatment at all. Interestingly, survival with active surveillance was comparable to radiation therapy, which yielded about 43 months.18PubMed. Active Surveillance for Early Stage Lung Cancer These findings suggest that for selected patients with slow-growing early lung cancer, watchful monitoring can be a reasonable alternative to immediate intervention.
For prostate cancer, the economic case is also compelling. A simulation of 120,000 men initiating active surveillance estimated per-patient cost savings of over $16,000 compared with immediate curative treatment over five years. Even at 10 years, active surveillance still saved nearly $10,000 per patient, though the cost advantage narrowed over time as more men eventually required treatment.19PubMed Central. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis
Living with a Diagnosis You Are Not Treating
Telling someone they have cancer and then telling them you are not going to treat it creates a psychological tension that is hard to overstate. For prostate cancer patients on active surveillance, cancer-specific anxiety is a real and measurable concern. A large prospective study found that about 29% of men experienced prostate-cancer-related anxiety after their first year on active surveillance. The encouraging news is that this anxiety decreased over time, dropping by roughly half after seven and a half years.20PubMed Central. Long term cancer-specific anxiety in men undergoing active surveillance for prostate cancer: findings from a large prospective cohort
Structured support can help. A pilot study of a group-based telehealth program for men on active surveillance found that about three quarters of participants reported improved communication with their clinicians, greater knowledge about their condition, and increased confidence in their healthcare decisions. About two-thirds said the program specifically increased their knowledge about active surveillance and supported their decision to continue it.21PubMed Central. Feasibility and Acceptability of a Group-Based Telehealth Stress Management and Resilience Training Intervention for Men with Prostate Cancer on Active Surveillance The results suggest that some of the anxiety is rooted in uncertainty and lack of information rather than in the cancer itself.
Telling Indolent from Aggressive at the Molecular Level
One of the biggest challenges with slow-growing cancers is that they sometimes look identical to aggressive cancers under a microscope, at least in the early stages. Researchers are working to develop molecular tools that can distinguish indolent from aggressive disease before it declares itself through behavior. In prostate cancer, genome-wide association studies have identified risk alleles that may help classify low-grade tumors by their potential for progression, information that could guide which men on active surveillance need closer monitoring.22PubMed Central. Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer
Similar work is happening in blood cancers. Researchers have attempted to identify gene expression signatures that distinguish the indolent from the aggressive phenotype in splenic marginal zone lymphoma, a rare type of non-Hodgkin lymphoma, by comparing gene activity patterns against more aggressive lymphomas and healthy cells.23Cancer Research. Abstract LB-345: Unique molecular identifiers of indolent versus aggressive phenotyping in non-Hodgkin lymphoma: Spotlight on SMZL This kind of molecular profiling is still largely in the research phase, but the goal is practical: give clinicians a way to tell at diagnosis whether a cancer is likely to sit quietly or eventually cause trouble, so treatment decisions can be tailored to the actual threat rather than the worst-case scenario.
Why Large Animals Get Cancer Less Than Expected
An observation from comparative biology adds an unexpected dimension to the question of slow-growing cancers. Logically, an animal with more cells should have a higher lifetime risk of cancer, since each cell is an opportunity for a cancerous mutation. But large, long-lived animals do not show higher cancer rates. This lack of correlation between body size and cancer risk is known as Peto’s paradox, and it suggests that natural mechanisms can suppress cancer far more effectively than what happens in human cells.24PubMed Central. Peto’s Paradox: evolution’s prescription for cancer prevention Elephants, whales, and other massive species appear to have evolved enhanced tumor suppression strategies, with extra copies of tumor-suppressor genes being one documented mechanism in elephants.
Researchers are studying these species not just out of curiosity but with the explicit hope of uncovering novel therapeutic approaches for humans.25Evolution. Beyond Peto’s paradox: expanding the study of cancer resistance across species Understanding how nature keeps cancer slow or dormant in large-bodied species could eventually inform strategies for managing indolent human cancers, or even preventing the transition from indolent to aggressive disease. The field is young, and no direct therapies have emerged yet, but the logic is sound: evolution has already solved the problem of keeping cancers in check over long lifespans. Medicine just has to figure out how.